Publication | Closed Access
Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients
219
Citations
16
References
2001
Year
Hospital AdmissionsChronic Viral HepatitisChronic Hepatitis CLogistic AnalysisHospital MedicineHepatic DisordersViral HepatitisClinical EpidemiologyPublic HealthClinical HepatologyHospital EpidemiologyChronic Viral InfectionHivClinical Infectious DiseaseHiv-infected PatientsAids PathogenesisEpidemiologyHepatologyHepatitis CHospital ChartsTreatment And PreventionGlobal HealthAntiviral TherapyHepatitisAcute Liver FailureMedicine
To assess the impact of chronic viral liver disease (CVLD) on hospital admissions and death in HIV-infected patients since the introduction of highly active antiretroviral therapy, all hospital charts, from January 1996 to December 2000, in a large HIV/AIDS reference center in Madrid were reviewed. Discharge diagnosis, complications during the inpatient period, and number and causes of death were recorded. A total of 1334 hospital admissions involving 875 HIV-infected individuals was recorded. Up to 82% of them were either active or former intravenous drug users. Overall, 158 (11.8%) were admitted because of complications of CVLD, or developed complications of CVLD during their admission for another reason. The absolute number and proportion of admissions caused by CVLD increased over time, from 9.4% (31 of 330) in 1996 to 16% (46 of 287) in 2000 (p < 0.05). Likewise, the total number and proportion of deaths due to CVLD increased from 9.3% (5 of 54) in 1996 to 45% (9 of 20) in 2000 (p < 0.05). Chronic hepatitis C was the only etiology in nearly three-quarters of patients who were admitted or died of CVLD. In conclusion, the proportion of hospital admissions caused by liver failure in HIV-infected patients has increased in the last 5 years, accounting for 16% of cases in 2000. End-stage liver disease currently represents 45% of causes of in-hospital death among HIV-infected individuals. Therefore, strategies to prevent infection by hepatitis viruses (hepatitis B vaccine) and specific treatment (interferon plus ribavirin for hepatitis C virus) should be encouraged among HIV-infected persons.
| Year | Citations | |
|---|---|---|
Page 1
Page 1